Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. Three stocks that are down over ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer ( PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

Chasing sky-high dividends could be setting you up for a painful payout cut. Find out 2 popular high-yield stocks flashing ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company struggles to gain investor interest in its ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...

Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of ...

Jim Cramer tackled Pfizer’s situation on Mad Money, warning viewers not to be lured by its juicy 7.7% dividend yield. He ...